<DOC>
	<DOCNO>NCT02559622</DOCNO>
	<brief_summary>The purpose study explore effect treatment 300 mg 150 mg secukinumab ( administered weekly 4 week follow four-weekly administration ) endothelial dysfunction arterial stiffness 12 week 52 week subject chronic plaque-type psoriasis . Furthermore soluble biomarkers assess evaluate influence secukinumab cardiovascular risk . Magnetic resonance imaging ( MRI ) perform subpopulation ass treatment effect arterial vessel wall morphometry atherosclerosis prone vascular bed .</brief_summary>
	<brief_title>Evaluation Cardiovascular Risk Markers Psoriasis Patients Treated With Secukinumab</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Chronic moderate severe plaque type psoriasis least 6 month prior randomization PASI score â‰¥ 10 randomization . Inadequate response , intolerance contraindication cyclosporine , methotrexate psoralen plus ultraviolet A light treatment ( PUVA ) document patient 's medical history report patient determine investigator screening . Relative contraindication interference patient 's lifestyle treatment accept . Key Forms psoriasis chronic plaquetype ( e.g. , pustular , erythrodermic guttata psoriasis ) screen randomization . Ongoing use prohibit psoriasis nonpsoriasis treatment . Washout period adhere .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>